Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tina Cheng

Showing results (51-60 of 62) with videos related to

Pageof 7
Sort By:
CMAJ Open|July 5, 2022
Stage migration of testicular germ cell tumours in Alberta, Canada, during the COVID-19 pandemic: a retrospective cohort studyRichard Lee-Ying, Dylan E O'Sullivan, Richard Gagnon, et al.
Cancers|January 11, 2022
CANDIED: A Pan-Canadian Cohort of Immune Checkpoint Inhibitor-Induced Insulin-Dependent Diabetes MellitusThiago P Muniz, Daniel V Araujo, Kerry J Savage, et al.
The Oncologist|April 3, 2023
Development and Validation of a Prognostic Risk Model for Patients with Advanced Melanoma Treated with Immune Checkpoint InhibitorsIgor Stukalin, Vishal Navani, Mehul Gupta, et al.
Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada|April 7, 2010
Canadian consensus guidelines for the management of testicular germ cell cancerLori Wood, Christian Kollmannsberger, Michael Jewett, et al.
Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada|November 27, 2023
High-dose chemotherapy with autologous stem-cell transplantation for relapsed metastatic germ cell tumors The Alberta experienceHanbo Zhang, Nimira S Alimohamed, Naveen S Basappa, et al.
European Journal of Cancer (Oxford, England : 1990)|May 11, 2021
Outcomes of patients with solid tumour malignancies treated with first-line immuno-oncology agents who do not meet eligibility criteria for clinical trialsChun L Gan, Igor Stukalin, Daniel E Meyers, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 15, 2009
Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter studyDaniel Y C Heng, Wanling Xie, Meredith M Regan, et al.
Clinical and Translational Science|February 16, 2024
Biomarker and pharmacodynamic activity of the transforming growth factor-beta (TGFβ) inhibitor SAR439459 as monotherapy and in combination with cemiplimab in a phase I clinical study in patients with advanced solid tumorsDebbie Robbrecht, Jean-Jacques Grob, Oliver Bechter, et al.
Cancer Medicine|November 13, 2019
Large retroperitoneal lymphadenopathy and increased risk of venous thromboembolism in patients receiving first-line chemotherapy for metastatic germ cell tumors: A study by the global germ cell cancer group (G3)Ben Tran, Jose M Ruiz-Morales, Enrique Gonzalez-Billalabeitia, et al.
European Urology Focus|October 9, 2020
A Risk-benefit Analysis of Prophylactic Anticoagulation for Patients with Metastatic Germ Cell Tumours Undergoing First-line ChemotherapyChristian Daniel Fankhauser, Ben Tran, Manuel Pedregal, et al.
Pageof 7

Showing results (51-60 of 62) with videos related to

Sort By:
Pageof 7
CMAJ Open|July 5, 2022
Stage migration of testicular germ cell tumours in Alberta, Canada, during the COVID-19 pandemic: a retrospective cohort studyRichard Lee-Ying, Dylan E O'Sullivan, Richard Gagnon, et al.
Cancers|January 11, 2022
CANDIED: A Pan-Canadian Cohort of Immune Checkpoint Inhibitor-Induced Insulin-Dependent Diabetes MellitusThiago P Muniz, Daniel V Araujo, Kerry J Savage, et al.
The Oncologist|April 3, 2023
Development and Validation of a Prognostic Risk Model for Patients with Advanced Melanoma Treated with Immune Checkpoint InhibitorsIgor Stukalin, Vishal Navani, Mehul Gupta, et al.
Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada|April 7, 2010
Canadian consensus guidelines for the management of testicular germ cell cancerLori Wood, Christian Kollmannsberger, Michael Jewett, et al.
Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada|November 27, 2023
High-dose chemotherapy with autologous stem-cell transplantation for relapsed metastatic germ cell tumors The Alberta experienceHanbo Zhang, Nimira S Alimohamed, Naveen S Basappa, et al.
European Journal of Cancer (Oxford, England : 1990)|May 11, 2021
Outcomes of patients with solid tumour malignancies treated with first-line immuno-oncology agents who do not meet eligibility criteria for clinical trialsChun L Gan, Igor Stukalin, Daniel E Meyers, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 15, 2009
Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter studyDaniel Y C Heng, Wanling Xie, Meredith M Regan, et al.
Clinical and Translational Science|February 16, 2024
Biomarker and pharmacodynamic activity of the transforming growth factor-beta (TGFβ) inhibitor SAR439459 as monotherapy and in combination with cemiplimab in a phase I clinical study in patients with advanced solid tumorsDebbie Robbrecht, Jean-Jacques Grob, Oliver Bechter, et al.
Cancer Medicine|November 13, 2019
Large retroperitoneal lymphadenopathy and increased risk of venous thromboembolism in patients receiving first-line chemotherapy for metastatic germ cell tumors: A study by the global germ cell cancer group (G3)Ben Tran, Jose M Ruiz-Morales, Enrique Gonzalez-Billalabeitia, et al.
European Urology Focus|October 9, 2020
A Risk-benefit Analysis of Prophylactic Anticoagulation for Patients with Metastatic Germ Cell Tumours Undergoing First-line ChemotherapyChristian Daniel Fankhauser, Ben Tran, Manuel Pedregal, et al.
Pageof 7